Fuji Pharma Co

Fuji Pharma Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fuji Pharma Co (4554.T) as of Oct 22, 2026 is 6.46 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 5.21 B JPY — a change of 23.98% (higher).

EBITDA

6.46 BJPY

YoY

23.98%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fuji Pharma Co is 2025 6.46 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fuji Pharma Co was 2024 5.21 B JPY. It decreases by 23.98% higher compared to the previous year.

The Fuji Pharma Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
5.17 B JPY
Jan 1, 2019
4.79 B JPY
Jan 1, 2020
3.76 B JPY
Jan 1, 2021
4.02 B JPY
Jan 1, 2022
4.72 B JPY
Jan 1, 2023
5.00 B JPY
Jan 1, 2024
5.21 B JPY
Jan 1, 2025
6.46 B JPY
The Fuji Pharma Co EBITDA history
YEAREBITDAYoY
6.46 BJPY+23.98%
5.21 BJPY+4.24%
5.00 BJPY+5.95%
4.72 BJPY+17.45%
4.02 BJPY+6.75%
3.76 BJPY-21.37%
4.79 BJPY-7.48%
5.17 BJPY+2.13%
5.07 BJPY+18.31%
4.28 BJPY+6.70%
4.01 BJPY+4.61%
3.84 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fuji Pharma Co Stock analysis

What does Fuji Pharma Co do? Fuji Pharma Co Ltd is a Japanese company specializing in the healthcare industry. The company was founded in 2001 and is headquartered in Tokyo, Japan. It is listed on the Tokyo Stock Exchange and employs over 1,000 employees. Fuji Pharma's business model is to provide its customers with innovative and high-quality products that contribute to improving health and well-being. The company specializes in several business areas, including the development, manufacturing, and marketing of pharmaceutical products, production of OEM products for other companies, and manufacturing of dietary supplements and cosmetics. An important area for Fuji Pharma is the development and production of pharmaceuticals. The company ensures that its medications meet the highest requirements and international standards. This includes research and development of new products. The company has its own research department specializing in the development of medications that can be used in serious diseases such as cancer, diabetes, and cardiovascular diseases. In addition, Fuji Pharma is also involved in the production of OEM products for other companies. The company ensures the manufacture of medications and medical products for other pharmaceutical companies, meeting the highest quality standards and customer requirements. Fuji Pharma is proud to be a trusted partner for its customers and provides its services according to the requirements of its customers. In addition to these two divisions, Fuji Pharma also produces dietary supplements and cosmetics for the domestic and international markets. These products are designed for consumers who want to improve their health and well-being. The company places great emphasis on the development of natural and safe ingredients for its products and ensures the highest standards of quality and safety. Fuji Pharma has also specialized in the Japanese market for medical devices, particularly in the field of home respiratory devices. The company has developed a new generation of respiratory therapy devices that are safe and easy to use, providing better well-being and quality of life for patients with respiratory diseases. In addition to its business areas, Fuji Pharma also has various products in its portfolio that are known for their quality and effectiveness. One such product is "Efil," a medication used in the treatment of erectile dysfunction disorders. The medication is available in Japan and other Asian countries and has already been used by over 200,000 patients. Fuji Pharma continuously strives to improve its research and development activities and develop new innovative products and services for the healthcare industry. The company aims to bring its products and services to the international market and satisfy its customers in Japan and worldwide. Fuji Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fuji Pharma Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fuji Pharma Co is 6.46 B JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fuji Pharma Co changed from 5.21 B JPY to 6.46 B JPY, representing a 23.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Fuji Pharma Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Fuji Pharma Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fuji Pharma Co

All Key Metrics — Fuji Pharma Co